Article Text

Download PDFPDF

3PC-040 Radiochemical purity determination of 177Lu-PSMA-617: development and validation of a high-performance liquid chromatography analytical method
  1. A Sallé1,
  2. J Fouillet1,
  3. C Donzé1,
  4. L Rubira1,
  5. C Fersing1,2
  1. 1Institut Régional du Cancer de Montpellier ICM, Nuclear Medicine Department- Radiopharmacy Unit, Montpellier, France
  2. 2Institut des Biomolécules Max Mousseron IBMM, F9 Team ‘Aminoacids- Peptides And Proteins’, Montpellier, France


Background and Importance 177Lu-PSMA-617 is a treatment of progressive, metastatic, castration-resistant prostate cancers expressing PSMA receptors, previously treated with taxane and at least one second-generation hormone therapy. 177Lu-PSMA-617 is a radiopharmaceutical drug with a marketing authorisation and is manufactured industrially (PLUVICTO®, Novartis). However, it can also be prepared in-house, especially for preclinical applications. Thus, quality control procedures are required to determine radiochemical purity (RCP).

Aim and Objectives To develop and validate a radio-high-performance liquid chromatography (HPLC) analysis method to measure RCP of 177Lu-PSMA-617.

Material and Methods Radio-HPLC analyses were carried out on an apparatus equipped with a C18 column and a radioactivity detector. Three commercial 177Lu-PSMA-617 batches were used as samples. The parameters considered for method validation were specificity, linearity, accuracy, precision, robustness, limits of detection (LOD) and limits of quantification (LOQ). Means, standard deviations and coefficient of variation (CV) for RCP, retention time (tr) and recovery were calculated. Linear regression coefficient R2 was computed for linearity.

Results Radiochemical identification of 177Lu-PSMA-617 consisted in 10 analyses of each three commercial batches and showed a consistent tr of 10.07 min (CV% < 0.1). Recovery was excellent, with 12.87 ± 0.06 MBq recovered at column outlet for a 12.2 MBq injected activity. The addition of radio-impurities in known quantities validated the accuracy of the method (differences between measured RCP and theoretical RCP ranging from 101.57% to 105.52%). CV% of RCP and tr values over 12 measures of a single batch were respectively <0.11% and <0.12%, which confirmed the repeatability of the method. Forced degradation conditions in the presence of acid, base, oxidative stress or heating led to the formation in situ of impurities with a tr largely different from the analyte, confirming the specificity of the method. LOQ and LOD were 0.68 and 0.21 MBq/mL, respectively, and the radiodetector response was linear from 2 to 300 MBq/mL (R2 = 0.9977). Robustness was found to be limited as the mean tr values varied by -4.8% when the column was heated to 50 °C instead of 25 °C.

Conclusion and Relevance A radio-HPLC method for the quality control of 177Lu-PSMA-617 was validated and can be used for in-house preparations for preclinical purposes of this radioactive drug.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.